The availability of these generics is still unclear as the patent for Entresto does not expire until July 15, 2025. The Food and Drug Administration (FDA) has approved the first generics of Entresto ® ...
East Hanover, NJ, Novartis announced today that the US Food and Drug Administration (FDA) has approved Entresto™ (sacubitril/valsartan) tablets, previously known as ...
ENTRESTO® (sacubitril/valsartan) tablets 24/26 mg, 49/51 mg, 97/103 mg is a prescription medicine used to treat adults with long-lasting (chronic) heart failure to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results